The HLA system: Genetics, immunology, clinical testing, and clinical implications

Yonsei Medical Journal

Volumn 48, Issue 1, 2007, Pages 11-23

  Choo, Sung Yoon ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Histocompatibility testing; HLA; Major histocompatibility complex; Transplantation

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CIPROFLOXACIN; HFE PROTEIN; HLA A3 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN; VANCOMYCIN;

ACUTE LUNG INJURY; ALLELE; ALLOIMMUNIZATION; ANTIBODY SCREENING; ANTIGEN EXPRESSION; ARTICLE; BLOOD TRANSFUSION; CHROMOSOME 6; DISEASE ASSOCIATION; GENETIC ORGANIZATION; GENETIC POLYMORPHISM; GENOTYPE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOCHROMATOSIS; HLA MATCHING; HLA SYSTEM; HUMAN; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; LIVING DONOR; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MOLECULAR TYPING; NONHUMAN; ORGAN TRANSPLANTATION; PARENTAGE ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; RHEUMATOID ARTHRITIS; SEROLOGY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

BLOOD TRANSFUSION; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS;

EID: 33947124454     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2007.48.1.11     Document Type: Article

References (76)

1. Terasaki PI, ed. History of HLA: Ten recollections. Los Angeles: UCLA Tissue Typing Laboratory Press; 1990.
2. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987;329:512-8.
3. Beck S, Trowsdale J. The human major histocompatibility complex: lessons from the DNA sequence. Annu Rev Genomics Hum Genet 2000;1:117-37. http://www-immuno.path.cam.ac.uk/~immuno/mhc/mhc.html
4. Marsh SGE, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, et al. Nomenclature for factors of the HLA system, 2004. Tissue Antigens 2005;65:301-69.
5. Bjorkman PJ, Parham P. Structure, function and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 1990;59:253-88.
6. Bjorman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329: 506-12.
7. Madden DR, Gorga JC, Strominger JL, Wiley DC. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 1991;353: 321-5.
8. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med 2000;343:702-9.
9. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33-9.
10. Engelhard VH. Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 1994;12:181-207.
11. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-6.
12. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974;248:701-2.
13. Garrett TP, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 1989;342:692-6.
14. Stern LJ, Wiley DC. Antigenic peptide binding by class I and class II histocompatibility proteins. Structure 1994;2:245-51.
15. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998; 16:323-58.
16. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994;12:259-93.
17. van der Merwe PA, Davis SJ. Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 2003;21:659-84.
18. Parham P. Immunogenetics of killer-cell immunoglobulin-like receptors. Tissue Antigens 2003;62:194-200.
19. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964;204:998-1000.
20. Choo SY, Fan LA, Hansen JA. Allelic variations clustered in the antigen binding sites of HLA-Bw62 molecules. Immunogenetics 1993;37:108-13.
21. White TJ, Arnheim N, Erlich HA. The polymerase chain reaction. Trends Genet 1989;5:185-9.
22. The IMGT/HLA Sequence Database, http://www.ebi.ac.uk/imgt/h1a/
23. Petersdorf EW, Hansen JA. A comprehensive approach for typing the alleles of the HLA-B locus by automated sequencing. Tissue Antigens 1995;46:73-85.
24. Johnson AH, Rossen RD, Butter WT. Detection of allo-antibodies using a sensitive antiglobulin micro-cytotoxicity test: identification of low levels of preformed antibodies in accelerated allograft rejection. Tissue Antigens 1972;2:215-26.
25. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000;69:319-26.
26. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003;3:1488-1500.
27. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923-30.
28. Petersdorf EW, Malkki M. Human leukocyte antigen matching in unrelated donor hematopoietic cell transplantation. Semin Hematol 2005;42:76-84.
29. Buckley RH. 27. Transplantation immunology: organ and bone marrow. J Allergy Clin Immunol 2003;111(2 Suppl): S733-44.
30. Whitelegg A, Barber LD. The structural basis of T-cell allorecognition. Tissue Antigens 2004;63:101-8.
31. Hauptman PJ, O'Connor KJ. Procurement and allocation of solid organs for transplantation. N Engl J Med 1997;336:422-31.
32. http://www.unos.org
33. http://www.unos.org/policiesandbylaws/policies.asp?resources=true
34. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004;15:3256-62.
35. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000;70:887-95.
36. Terasaki PI, Cho Y, Takemoto S, Cecka M, Gjertson D. Twenty-year follow-up on the effect of HLA matching on kidney transplant survival and prediction of future twenty-year survival. Transplant Proc 1996;28:1144-5.
37. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995;333:333-6.
38. Thomas ED. Bone marrow transplantation: a review. Semin Hematol 1999;36(4 Suppl 7):95-103.
39. Schoemans H, Theunissen K, Maertens J, Boogaerts M, Verfaillie C, Wagner J. Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transplant 2006;38:83-93.
40. Martin PJ. Tbe role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplant 1990;6:283-9.
41. Cornelissen JJ, Lowenberg B. Developments in T-cell depletion of allogeneic stem cell grafts. Curr Opin Hematol 2000;7:348-52.
42. Storb R, Thomas ED, Buckner CD, Clift RA, Johnson FL, Fefer A, et al. Allogeneic marrow grafting for treatment of aplastic anemia. Blood 1974;43:157-80.
43. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1984;313:765-71.
44. Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991;51:443-7.
45. McCullough J, Perkins HA, Hansen J. The National Marrow Donor Program with emphasis on the early years. Transfusion 2006;46:1248-55.
46. Karanes C, Confer D, Walker T, Askren A, Keller C. Unrelated donor stem cell transplantation: the role of the National Marrow Donor Program. Oncology (Williston Park) 2003;17:1036-8,1043-4,1164-7. http://www.marrow.org/MEDIA/facts_figures.pdf
47. Hurley CK, Fernandez Vina M, Setterholm M. Maximizing optimal hematopoietic stem cell donor selection from registries of unrelated adult volunteers. Tissue Antigens 2003;61:415-24.
48. Petersdorf EW, Mickelson EM, Anasetti C, Martin PJ, Woolfrey AE, Hansen JA. Effect of HLA mismatches on the outcome of hematopoietic transplants. Curr Opin Immunol 1999;11:521-6.
49. Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99:4200-6.
50. Dickinson AM, Charron D. Non-HLA immunogenetics in hematopoietic stem cell transplantation. Curr Opin Immunol 2005;17:517-25.
51. Hurley CK, Baxter Lowe LA, Logan B, Karanes C, Anasetti C, Weisdorf D, et al. National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants. Biol Blood Marrow Transplant 2003;9: 610-5.
52. Jones DC, Young NT. Natural killer receptor repertoires in transplantation. Eur J Immunogenet 2003;30:169-76.
53. Lowdell MW. Natural killer cells in haematopoietic stem cell transplantation. Transfus Med 2003;13:399-404.
54. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol 1996;8:75-81.
55. Claas FH, Smeenk RJ, Schmidt R, van Steenbrugge GJ, Eernisse JG. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981;9:84-9.
56. Abou-Elella AA, Camarillo TA, Allen MB, Barclay S, Pierce JA, Holland HK, et al. Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Transfusion 1995;35:931-5.
57. Storb R, Thomas ED, Buckner DC, Appelbaum FR, Clift RA, Deeg HJ, et al. Marrow transplantation for aplastic anemia. Semin Hematol 1984;21:27-35.
58. van Marwijk-Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JW. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 1991;77:201-5.
59. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, van Dijk BA, van Putten WL, Claas FH, et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995;85:824-8.
60. McFarland JG, Anderson AJ, Slichter SJ. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates. Br J Haematol 1989;73:380-6.
61. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZ, Lister TA, Waters AH. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994;66:200-5.
62. International Forum. Detection of platelet-reactive anti-bodies in patients who are refractory to platelet transfusions, and the selection of compatible donors. Vox Sang 2003;84:73-88.
63. Rachel JM, Summers TC, Sinor LT, Plapp FV. Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing. Am J Clin Pathol 1988;90:63-8.
64. Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004;103:333-9.
65. Petz LD, Calhoun L, Yam P, Cecka M, Schiller G, Faitlowicz AR, et al. Transfusion-associated graft-versus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors. Transfusion 1993;33:742-50.
66. Shivdasani RA, Anderson KC. HLA homozygosity and shared HLA haplotypes in the development of transfusion-associated graft-versus-host disease. Leuk Lymphoma 1994;15:227-34.
67. Davey RJ. Transfusion-associated graft-versus-host disease and the irradiation of blood components. Immunol Invest 1995;24:431-4.
68. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985;25:573-7.
69. Kopko PM, Paglieroni TG, Popovsky MA, Muto KN, MacKenzie MR, Holland PV. TRALI: correlation of antigen-antibody and monocyte activation in donor-recipient pairs. Transfusion 2003;43:177-84.
70. Silliman CC, Paterson AJ, Dickey WO, Stroneck DF, Popovsky MA, Caldwell SA, et al. The association of biologically active lipids - with the development of transfusion-related acute lung injury: a retrospective study. Transfusion 1997;37:719-26.
71. Deaver JE, Leppert PC, Zaroulis CG. Neonatal alloimmune thrombocytopenic purpura. Am J Perinatol 1986; 3:127-31.
72. Valentin N, Vergracht A, Bignon JD, Cheneau ML, Blanchard D, Kaplan C, et al. HLA-DRw52a is involved in alloimmunization against PL-A1 antigen. Hum Immunol 1990;27:73-9.
73. Saito S, Ota M, Komatsu Y, Ota S, Aoki S, Koike K, et al. Serologic analysis of three cases of neonatal alloimmune thrombocytopenia associated with HLA antibodies. Transfusion 2003;43:908-17.
74. Thorsby E. Invited anniversary review: HLA associated diseases. Hum Immunol 1997;53:1-11.
75. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
76. Pena SD, Chakraborty R. Paternity testing in the DNA era. Trends Genet 1994;10:204-9.